This unique tumor immunology makes LS-associated CRC (LS-CRC) an ideal candidate for immune checkpoint inhibitors (ICIs) like PD-1/PD-L1 and CTLA-4 inhibitors.5 Here, CTLA4 is linked to Leigh syndrome.